106 Advanced Solid Tumors Clinical Trials in Los Angeles, CA (2026)

Q: How do I join a clinical trial in Los Angeles?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Los Angeles research site will contact you.

Recruiting Advanced Solid Tumors Studies in Los Angeles

NCT05579366Recruiting

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that ha...

Los Angeles, CAPHASE1884 participantsGenmab

View Study Details

NCT05768139Recruiting

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with...

Los Angeles, CAPHASE1880 participantsEli Lilly and Company

View Study Details

NCT06741644Recruiting

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monother...

Los Angeles, CAPHASE1800 participantsCStone Pharmaceuticals

View Study Details

NCT05417594Recruiting

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participan...

Los Angeles, CAPHASE1695 participantsAstraZeneca

View Study Details

NCT06581432Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of th...

Los Angeles, CAPHASE2588 participantsBoehringer Ingelheim

View Study Details

NCT07522073Recruiting

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC)....

Los Angeles, CAPHASE3588 participantsIncyte Corporation

View Study Details

NCT07066657Recruiting

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic...

Los Angeles, CAPHASE1572 participantsArriVent BioPharma, Inc.

View Study Details

NCT05836324Recruiting

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors....

Los Angeles, CAPHASE1570 participantsIncyte Corporation

View Study Details

NCT03526835Recruiting

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC...

Los Angeles, CAPHASE1560 participantsMerus N.V.

View Study Details

NCT04657068Recruiting

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can ...

Los Angeles, CAPHASE1542 participantsArtios Pharma Ltd

View Study Details

NCT07160725Recruiting

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors...

Los Angeles, CAPHASE1540 participantsBristol-Myers Squibb

View Study Details

NCT06589596Recruiting

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity...

Los Angeles, CAPHASE1525 participantsBeOne Medicines

View Study Details

NCT07038343Recruiting

Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when admi...

Los Angeles, CAPHASE1480 participantsAvenzo Therapeutics, Inc.

View Study Details

NCT06051695Recruiting

A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell l...

Los Angeles, CAPHASE1474 participantsA2 Biotherapeutics Inc.

View Study Details

NCT04855656Recruiting

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced sol...

Los Angeles, CAPHASE1464 participantsDebiopharm International SA

View Study Details

NCT05489211Recruiting

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Ad...

Los Angeles, CAPHASE2454 participantsAstraZeneca

View Study Details

NCT06914128Recruiting

A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors

The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferas...

Los Angeles, CAPHASE1450 participantsBayer

View Study Details

NCT07094113Recruiting

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combin...

Los Angeles, CAPHASE1434 participantsAmgen

View Study Details

NCT06465069Recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The ...

Los Angeles, CAPHASE1420 participantsEli Lilly and Company

View Study Details

NCT06697197Recruiting

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors....

Los Angeles, CAPHASE1413 participantsBristol-Myers Squibb

View Study Details

NCT04913285Recruiting

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors....

Los Angeles, CAPHASE1400 participantsPierre Fabre Medicament

View Study Details

NCT06545331Recruiting

Study of XB010 in Subjects With Solid Tumors

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with lo...

Los Angeles, CAPHASE1396 participantsExelixis

View Study Details

NCT06625775Recruiting

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced...

Los Angeles, CAPHASE1392 participantsTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

View Study Details

NCT06998407Recruiting

Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in pat...

Los Angeles, CAPHASE1380 participantsAvenzo Therapeutics, Inc.

View Study Details

NCT07397338Recruiting

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanc...

Los Angeles, CAPHASE1370 participantsRevolution Medicines, Inc.

View Study Details

NCT05669430Recruiting

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care....

Los Angeles, CAPHASE1365 participantsGV20 Therapeutics

View Study Details

NCT05098132Recruiting

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced...

Los Angeles, CAPHASE1364 participantsSynthekine

View Study Details

NCT05533697Recruiting

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab....

Los Angeles, CAPHASE1361 participantsModernaTX, Inc.

View Study Details

NCT06554795Recruiting

First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors

A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors...

Los Angeles, CAPHASE1360 participantsDualityBio Inc.

View Study Details

NCT04198766Recruiting

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administ...

Los Angeles, CAPHASE1340 participantsInhibrx Biosciences, Inc

View Study Details

NCT05981703Recruiting

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced so...

Los Angeles, CAPHASE1337 participantsBeOne Medicines

View Study Details

NCT05720117Recruiting

A Study of PYX-201 in Advanced Solid Tumors

The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (OR...

Los Angeles, CAPHASE1330 participantsPyxis Oncology, Inc

View Study Details

NCT06736704Recruiting

SNV4818 in Participants With Advanced Solid Tumors

This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are i...

Los Angeles, CAPHASE1320 participantsPikavation Therapeutics, Inc.

View Study Details

NCT05068583Recruiting

Liquid Biopsies in Pediatric Solid Tumors

This study is being done to determine if traces of tumor can be found in the blood before, during, and after patients stop treatment. We will analyze the tumor material to see if it is similar to tumo...

Los Angeles, CA320 participantsChildren's Hospital Los Angeles

View Study Details

NCT07090499Recruiting

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-0...

Los Angeles, CAPHASE1310 participantsPfizer

View Study Details

NCT06233942Recruiting

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and ...

Los Angeles, CAPHASE1308 participantsBeOne Medicines

View Study Details

NCT04585750Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tum...

Los Angeles, CAPHASE1300 participantsPMV Pharmaceuticals, Inc

View Study Details

NCT05941507Recruiting

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expa...

Los Angeles, CAPHASE1300 participantsLigaChem Biosciences, Inc.

View Study Details

NCT06026410Recruiting

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with ad...

Los Angeles, CAPHASE1300 participantsKura Oncology, Inc.

View Study Details

NCT07335497Recruiting

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) ...

Los Angeles, CAPHASE1290 participantsCrescent Biopharma, Inc.

View Study Details

NCT05101070Recruiting

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

The primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of S-531011. The primar...

Los Angeles, CAPHASE1282 participantsShionogi

View Study Details

NCT06004245Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumo...

Los Angeles, CAPHASE1280 participantsVividion Therapeutics, Inc.

View Study Details

NCT07339176Recruiting

Intratumoral N17350 in Advanced Solid Tumors

The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future st...

Los Angeles, CAPHASE1275 participantsOnchilles Pharma Inc

View Study Details

NCT06840886Recruiting

A Study of PHST001 in Advanced Solid Tumors

This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy...

Los Angeles, CAPHASE1272 participantsPheast Therapeutics

View Study Details

NCT07141706Recruiting

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design and a BOIN design to identify the MTD or MAD of DB-1317; Phase 1b includes up t...

Los Angeles, CAPHASE1253 participantsDualityBio Inc.

View Study Details

NCT06227377Recruiting

QTX3034 in Patients With KRAS G12D Mutation

Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab....

Los Angeles, CAPHASE1250 participantsQuanta Therapeutics

View Study Details

NCT06242470Recruiting

A Study of MGC026 in Participants With Advanced Solid Tumors

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, ...

Los Angeles, CAPHASE1250 participantsMacroGenics

View Study Details

NCT06682793Recruiting

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head a...

Los Angeles, CAPHASE1240 participantsA2 Biotherapeutics Inc.

View Study Details

NCT05970497Recruiting

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid ...

Los Angeles, CAPHASE1240 participantsKrystal Biotech, Inc.

View Study Details

NCT06413680Recruiting

A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies

This study is researching an experimental drug called REGN10597 (called "study drug"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study i...

Los Angeles, CAPHASE1240 participantsRegeneron Pharmaceuticals

View Study Details

NCT06480552Recruiting

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

The primary objectives of this trial are to: * Characterize the safety and tolerability of TEV-56278 * Determine the Recommended Phase 2 Dose (RP2D) * Evaluate antitumor activity of TEV-56278 (Part 2...

Los Angeles, CAPHASE1240 participantsTeva Branded Pharmaceutical Products R&D LLC

View Study Details

NCT06797336Recruiting

A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0253 in adult participants wit...

Los Angeles, CAPHASE1240 participantsPAQ Therapeutics, Inc.

View Study Details

NCT05985655Recruiting

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617-001 in participants with advanced solid tumors....

Los Angeles, CAPHASE1230 participantsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

View Study Details

NCT04939610Recruiting

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

Fibroblast activation protein (FAP) is a cell surface protein that is highly expressed on the surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial c...

Los Angeles, CAPHASE1222 participantsNovartis Pharmaceuticals

View Study Details

NCT06060613Recruiting

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors....

Los Angeles, CAPHASE1208 participantsObsidian Therapeutics, Inc.

View Study Details

NCT05902988Recruiting

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers....

Los Angeles, CAPHASE1200 participantsVolastra Therapeutics, Inc.

View Study Details

NCT04064359Recruiting

Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are norma...

Los Angeles, CAPHASE1200 participantsOxford BioTherapeutics Ltd

View Study Details

NCT04219254Recruiting

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD-1 or Anti-PD-L1...

Los Angeles, CAPHASE1197 participantsBioInvent International AB

View Study Details

NCT05422911Recruiting

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have succe...

Los Angeles, CAPHASE2192 participantsSun Pharmaceutical Industries Limited

View Study Details

NCT06810544Recruiting

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an op...

Los Angeles, CAPHASE1191 participantsTango Therapeutics, Inc.

View Study Details

NCT06251310Recruiting

SW-682 in Advanced Solid Tumors

This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with...

Los Angeles, CAPHASE1186 participantsSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

View Study Details

NCT07169734Recruiting

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P...

Los Angeles, CAPHASE1180 participantsAlentis Therapeutics AG

View Study Details

NCT07374848Recruiting

Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer....

Los Angeles, CAPHASE1180 participantsZai Lab (Shanghai) Co., Ltd.

View Study Details

NCT06747585Recruiting

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

Los Angeles, CAPHASE1170 participantsAlentis Therapeutics AG

View Study Details

NCT06625593Recruiting

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agent...

Los Angeles, CAPHASE1168 participantsBeOne Medicines

View Study Details

NCT06603844Recruiting

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and hav...

Los Angeles, CAPHASE1156 participantsCorbus Pharmaceuticals Inc.

View Study Details

NCT07123103Recruiting

A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion co...

Los Angeles, CAPHASE1150 participantsExelixis

View Study Details

NCT06586957Recruiting

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for ...

Los Angeles, CAPHASE1150 participantsNiKang Therapeutics, Inc.

View Study Details

NCT04142437Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with ...

Los Angeles, CA150 participantsBayer

View Study Details

NCT04851119Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to tr...

Los Angeles, CAPHASE1147 participantsChildren's Oncology Group

View Study Details

NCT06898450Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

The goal of this clinical trial is to learn if NDI-219216 is safe for patients, and if NDI-219216 might be a possible treatment for advanced solid tumors in the later phases of the study. The main qu...

Los Angeles, CAPHASE1134 participantsNimbus Wadjet, Inc.

View Study Details

NCT07602842Recruiting

A Study of IDP-001 in Advanced or Metastatic Solid Tumors

This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous ...

Los Angeles, CAPHASE1132 participantsInduPro, Inc.

View Study Details

NCT05394103Recruiting

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monother...

Los Angeles, CAPHASE1130 participantsQurient Co., Ltd.

View Study Details

NCT06462794Recruiting

First In Human Study of CX-801 in Advanced Solid Tumors

The purpose of this first-in-human study, CTMX-801-101, is to characterize the safety, tolerability, and antitumor activity of CX-801 as monotherapy and in combination with pembrolizumab in adult part...

Los Angeles, CAPHASE1121 participantsCytomX Therapeutics

View Study Details

NCT06425926Recruiting

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary ef...

Los Angeles, CAPHASE1117 participantsGeorgiamune Inc

View Study Details

NCT06028074Recruiting

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clini...

Los Angeles, CAPHASE1111 participantsGeorgiamune Inc

View Study Details

NCT04762641Recruiting

This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL503 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immu...

Los Angeles, CAPHASE1100 participantsABL Bio, Inc.

View Study Details

NCT07196644Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab ad...

Los Angeles, CAPHASE2100 participantsAbbVie

View Study Details

NCT06778863Recruiting

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation....

Los Angeles, CAPHASE190 participantsClasp Therapeutics, Inc.

View Study Details

NCT05103683Recruiting

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer...

Los Angeles, CAPHASE190 participantsTORL Biotherapeutics, LLC

View Study Details

NCT05327010Recruiting

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment a...

Los Angeles, CAPHASE288 participantsNational Cancer Institute (NCI)

View Study Details

NCT06994806Recruiting

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

The goal of this clinical trial is to learn if KQB168 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB168. The main questions it aims to answer are: * ...

Los Angeles, CAPHASE184 participantsKumquat Biosciences Inc.

View Study Details

NCT06730347Recruiting

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 60 participants will be e...

Los Angeles, CAPHASE280 participantsMacroGenics

View Study Details

NCT07207707Recruiting

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

The goal of this trial is to learn if KQB548 works to treat patients with advanced solid malignancies with a KRAS G12D mutation. It will also learn about the safety of KQB548. The main questions it ai...

Los Angeles, CAPHASE178 participantsKumquat Biosciences Inc.

View Study Details

NCT06126276Recruiting

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbocicli...

Los Angeles, CAPHASE270 participantsNational Cancer Institute (NCI)

View Study Details

NCT06005740Recruiting

A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid...

Los Angeles, CAPHASE170 participantsTORL Biotherapeutics, LLC

View Study Details

NCT05471856Recruiting

A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

This study is open to adults with different types of advanced cancer. People can take part if previous treatment was not successful, or no treatment exists. The purpose of this study is to find the h...

Los Angeles, CAPHASE166 participantsBoehringer Ingelheim

View Study Details

NCT06444815Recruiting

A Study of VET3-TGI in Patients With Solid Tumors

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET...

Los Angeles, CAPHASE160 participantsKaliVir Immunotherapeutics

View Study Details

NCT04412616Recruiting

ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies

This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Mal...

Los Angeles, CAPHASE160 participantsChangchun Intellicrown Pharmaceutical Co. LTD

View Study Details

NCT06721689Recruiting

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

The phase 1 primary objective is to determine the pediatric recommended phase 2 dose (RP2D) of PEEL-224 as a single agent (phase 1A) and in combination with vincristine and temozolomide (phase 1B). Th...

Los Angeles, CAPHASE159 participantsTheodore Laetsch

View Study Details

NCT06941272Recruiting

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

Researchers are looking for new ways to treat children with hepatoblastoma or rhabdomyosarcoma (RMS) that has relapsed or is refractory: * Hepatoblastoma is a common liver cancer in babies and very y...

Los Angeles, CAPHASE150 participantsMerck Sharp & Dohme LLC

View Study Details

NCT04928677Recruiting

A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

The purpose of this study to find out whether codrituzumab is a safe treatment that causes few or mild side effects in children and young adults who have solid tumors that express the protein GPC3. Th...

Los Angeles, CAPHASE150 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06187402Recruiting

A Study of LM-24C5 For Advanced Solid Tumors

To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors....

Los Angeles, CAPHASE149 participantsLaNova Medicines Limited

View Study Details

NCT06880549Recruiting

A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

The purpose of this study is to assess the safety and tolerability of mRNA-4106 monotherapy and of mRNA-4200 in combination with checkpoint inhibitor therapy in participants with solid tumors....

Los Angeles, CAPHASE142 participantsModernaTX, Inc.

View Study Details

NCT07517198Recruiting

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors....

Los Angeles, CAPHASE140 participantsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

View Study Details

NCT07337525Recruiting

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

The goal of this clinical trial is to learn about what doses of PLT012 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of PLT012...

Los Angeles, CAPHASE136 participantsPilatus Biosciences Inc

View Study Details

NCT03943004Recruiting

Trial of DFP-14927 in Advanced Solid Tumors

This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors....

Los Angeles, CAPHASE130 participantsDelta-Fly Pharma, Inc.

View Study Details

NCT07192432Recruiting

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers....

Los Angeles, CAPHASE127 participantsVironexis Biotherapeutics Inc.

View Study Details

NCT06943521Recruiting

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced s...

Los Angeles, CAPHASE127 participantsMitsubishi Tanabe Pharma America Inc.

View Study Details

NCT06694480Recruiting

Study of FID-022 in Participants With Advanced Solid Tumors

The goal of this Phase I Clinical Trial is to evaluate the safety and tolerability of FID-022 in patients with advanced solid tumors....

Los Angeles, CAPHASE124 participantsFulgent Pharma LLC.

View Study Details

NCT02693535Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or ...

Los Angeles, CAPHASE24,200 participantsAmerican Society of Clinical Oncology

View Study Details

NCT03486873Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this ex...

Los Angeles, CAPHASE33,500 participantsMerck Sharp & Dohme LLC

View Study Details

NCT05557045Recruiting

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway....

Los Angeles, CAPHASE1332 participantsJazz Pharmaceuticals

View Study Details

NCT04145622Recruiting

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. Th...

Los Angeles, CAPHASE1250 participantsDaiichi Sankyo

View Study Details

NCT04503265Recruiting

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dos...

Los Angeles, CAPHASE1122 participantsAtlasMedx, Incorporated

View Study Details

NCT04969315Recruiting

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of ca...

Los Angeles, CAPHASE190 participantsPortage Biotech

View Study Details

About Advanced Solid Tumors Clinical Trials in Los Angeles

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 106 advanced solid tumors clinical trials recruiting participants in Los Angeles, CA. These studies are seeking a combined 35,224 participants. Research is being sponsored by Genmab, Eli Lilly and Company, CStone Pharmaceuticals and 81 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Los Angeles — FAQ

Are there advanced solid tumors clinical trials in Los Angeles?

Yes, there are 106 advanced solid tumors clinical trials currently recruiting in Los Angeles, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Los Angeles?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Los Angeles research site will contact you about next steps.

Are clinical trials in Los Angeles free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Los Angeles studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 106 active trials in Los Angeles are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated September 4, 2026 from ClinicalTrials.gov